Journal for ImmunoTherapy of Cancer

POSTER PRESENTATION Open Access

Cyclic dinucleotides (CDNs) reversed T cells tolerance in anti-tumor immunotherapy

Juan Fu[1], Young Kim[2*], David Kanne[3], Meredith Leong[4], Qi Zeng[2], Rupashree Sen[5], Todd D Amstrong[6], Charles G Drake[7], Thomas Dubensky[4], Drew Pardoll[2], Shekhar Gadkare[2]

From 30th Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2015) National Harbor, MD, USA. 4-8 November 2015

One important barrier to cancer immunotherapy. We used cyclic dinucleotides (CDNs) and Listeria vaccine and LPS treated HA-specific CD8 tolerance B10. D2 mice. Our results demonstrated T cells IFN-gamma increased in CDNs and Listeria vaccine plus CDNs treatment groups. But CDNs didn't significantly increase Treg cells. The data showed CDNs can reverse established T cell tolerance that improved cancer immunotherapy in the future. We will further explore T cells tolerance in cancer bearing T cell tolerance mice model in vivo.

Authors' details
[1]Johns Hopkis Unversity, Baltimore, MD, USA. [2]Johns Hopkins University, Baltimore, MD, USA. [3]Aduro BioTech, Berkeley, CA, USA. [4]Aduro BioTech, Berkely, CA, USA. [5]Johns Hopkins Unversity, Baltimore, MD, USA. [6]Johns Hopins University, Baltimore, MD, USA. [7]Department of Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University,, Baltimore, MD, USA.

Published: 4 November 2015

doi:10.1186/2051-1426-3-S2-P268
Cite this article as: Fu *et al.*: Cyclic dinucleotides (CDNs) reversed T cells tolerance in anti-tumor immunotherapy. *Journal for ImmunoTherapy of Cancer* 2015 **3**(Suppl 2):P268.

[2]Johns Hopkins University, Baltimore, MD, USA
Full list of author information is available at the end of the article